TOP TEN perturbations for 39743_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39743_at
Selected probe(set): 203197_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39743_at (203197_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
LPS study 4 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-1.6824179Number of Samples:2 / 2
| Experimental | LPS study 4 (shRNA contr.) |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated / transduced MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
glioma study 17 (glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)
Relative Expression (log2-ratio):1.595664Number of Samples:3 / 3
| Experimental | glioma study 17 (glioblastoma; A2B5+) |
| Oligodendrocyte progenitor cells (OPC) isolated from high grade glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 66 ± 5 years old males. | |
| Control | non-tumor oligodendrocyte progenitor cell sample (cortex) |
| Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. |
kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample
Relative Expression (log2-ratio):-1.5884342Number of Samples:2 / 5
| Experimental | kidney transplantation study 15 (8 week) |
| CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH). | |
| Control | normal monocyte (CD14+) sample |
| CD14+ monocyte samples derived from healthy control subjects. |
tumor supernatant activation study 3 / untreated memory CD4 T-cell sample
Relative Expression (log2-ratio):-1.5814447Number of Samples:4 / 3
| Experimental | tumor supernatant activation study 3 |
| Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:--- | |
| Control | untreated memory CD4 T-cell sample |
| Memory (CD45RA-) CD4+ T-cells were isolated from peripheral blood of healthy female donors and incubated in X-VIVO 20 medium for 24 hours, before harvest for RNA isolation. |
LPS study 4 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):-1.5602684Number of Samples:2 / 2
| Experimental | LPS study 4 |
| MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:--- | |
| Control | mock treated MONO-MAC-6 cell sample |
| MONO-MAC-6 (MM6) cells mock treated. |
systemic onset JIA study 6 (baseline; placebo) / normal blood sample
Relative Expression (log2-ratio):-1.5587063Number of Samples:22 / 22
| Experimental | systemic onset JIA study 6 (baseline; placebo) |
| Whole blood samples collected from systemic juvenile idiopathic arthritis patients at baseline (day 1), prior to placebo treatment. Patients were 2 to 19 years of age with a confirmed diagnosis of febrile SJIA with high disease activity. aACR response was scored at day 15. Concomitant therapy with a prednisone equivalent (up to 1.0 mg/kg/day) and stable doses of nonsteroidal anti inflammatory drugs and methotrexate (≤20 mg/m2 per week) were permitted. | |
| Control | normal blood sample |
| Whole blood samples collected from healthy volunteers. |
zalypsis study 2 / untreated OPM1 cell sample
Relative Expression (log2-ratio):1.4772158Number of Samples:2 / 2
| Experimental | zalypsis study 2 |
| OPM1 multiple myeloma cells treated in vitro with zalypsis (5 nM), a novel marine-derived compound with potent antimyeloma activity. Cells were harvested at the beginning of induction of cell death (15-20% cell death as assessed by Annexin V-FITC staining). ATC code:--- | |
| Control | untreated OPM1 cell sample |
| OPM1 multiple myeloma cells untreated. |
tumor supernatant activation study 3 / memory T-cell activation study 1
Relative Expression (log2-ratio):-1.424284Number of Samples:4 / 3
| Experimental | tumor supernatant activation study 3 |
| Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:--- | |
| Control | memory T-cell activation study 1 |
| Memory (CD45RA-) CD4+ T-cells isolated from peripheral blood of healthy female donors were activated with anti-CD3/CD28 beads for 24hrs. |
PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample
Relative Expression (log2-ratio):-1.3871574Number of Samples:8 / 8
| Experimental | PMA; ionomycine study 2 |
| CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:--- | |
| Control | unstimulated CD4 memory T-cell sample |
| Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary)
Relative Expression (log2-ratio):1.3734188Number of Samples:2 / 3
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, malignant peripheral nerve sheath tumor of the soft tissue (subcutaneously implanted). |